NHE1 in macrophages promotes octanal/Olfr2-induced atherosclerosis via calcium-dependent ROS and NLRP3 inflammasome activation Authors: Tianhui Wang, Lan Wang, Qian Tian, Yuan Zhu, Lijuan Shao, Jiao Zeng, Yongchao Yu, Zhonglian Li, Xiaomeng Su, Juhai Chen, Ya Zhang, Xiangang Mo Published: 2025 ABSTRACT AbstractAtherosclerosis (AS) is the leading cause of global mortality and morbidity. Despite the elevated expression of sodium-hydrogen exchanger 1 (NHE1) and olfactory receptor 2 (Olfr2) in plaque macrophages, their interactions within the AS context remain poorly understood. In this study, ApoE−/− mice and RAW264.7 macrophages were employed to examine the impact of intraperitoneal octanal injection on atherosclerosis and NHE1 expression in vivo. In vitro analyses were conducted to assess NHE1 expression, activity, and inflammatory responses subsequent to treatment with octanal and an NHE1 inhibitor. Furthermore, the underlying mechanisms were investigated through RNA interference and calcium ion (Ca2+) chelation. In vivo, octanal aggravated AS by upregulating NHE1 within plaques, while NHE1 deficiency resulted in reduced plaque formation and inflammation. In vitro, octanal increased NHE1 expression and activity in a dose- and time-dependent manner in RAW264.7 cells, facilitating foam cell formation and inflammatory responses. NHE1 inhibitors effectively attenuated these effects. Mechanistically, RNA interference targeting Olfr2 or calcium chelation reduced octanal-induced NHE1 upregulation and associated inflammatory responses. These findings highlight NHE1 as a key downstream effector in the Octanal/Olfr2 signaling pathway, suggesting that targeting NHE1 may present a promising therapeutic approach for AS.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-28218-9.Keywords: Atherosclerosis, Sodium hydrogen exchanger 1, Octanal, Olfactory receptor 2, InflammationSubject terms: Cardiology, Diseases, Medical research Introduction Atherosclerosis (AS) is a chronic inflammatory disorder affecting large and medium-sized arteries, serving as the primary pathological basis for cardiovascular diseases such as coronary heart disease, stroke, and peripheral arterial disease, which together remain the leading global causes of mortality1. The pathology of AS involves lipid accumulation in the arterial wall and plaque formation, wherein monocytes and macrophages play pivotal roles by infiltrating the arterial intima, engulfing lipids, and forming foam cells. This process accelerates plaque growth and instability2,3, thereby impairing arterial structure and function and significantly increasing the risk of ischemic events, including myocardial infarction and stroke4,5. Despite rigorous management of blood pressure and glucose levels the use of lipid-lowering therapies like statins, ezetimibe, and evolocumab6,7, and the implementation of vascular interventions8, a considerable proportion of patients with AS remain at residual risk for cardiovascular events. This underscores the urgent need to further investigate novel mechanisms driving AS pathogenesis, offering new avenues for prevention and therapeutic strategies. Olfactory receptors in macrophages may serve as potential targets for developing strategies to prevent and treat AS 9. These receptors are encoded by a family of approximately 400 genes in humans and approximately 1100 in mice, forming a diverse group of proteins10. While most olfactory receptors are predominantly located in sensory organs, they are G protein-coupled receptors essential for generating odor perception and detecting other chemical signals9–11. Although their primary function is in olfactory perception, increasing evidence points to their presence in non-olfactory tissues, including spermatozoa, skin, and intestines12–14, where they carry out various non-olfactory biological functions. Within the immune system, olfactory receptors are expressed and perform critical roles. For example, the macrophage-associated olfactory receptor Olfr78 has been shown to mediate the lactate-induced transition of tumor-associated macrophages to the M2 phenotype15, which promotes tumorigenesis. In the lungs of mice, activation of olfactory receptors on macrophages triggers the production of monocyte chemoattractant protein-1, among other factors16. These findings demonstrate that olfactory receptors on immune cells have non-olfactory functions, including modulating macrophage phenotype and function by detecting both endogenous and exogenous chemical signals, thus influencing inflammation and tissue repair processes. Additionally, Orecchioni et al. 17 elucidated that Olfr2, an olfactory receptor on vascular macrophages, detects the lipid metabolite octanal, triggering an inflammatory response that contributes to the progression of AS. Octanal, a byproduct of lipid peroxidation, is commonly produced under oxidative stress conditions. It is a prevalent flavor compound in foods and is widely found in plant essential oils and food additives18,19. Both in physiological and pathological states, octanal can be generated through the metabolism of oleic acid, a fatty acid commonly found in the human diet. Research has identified octanal as a ligand for Olfr2, with Olfr2 activation leading to increased calcium concentrations and the production of reactive oxygen species (ROS) in downstream signaling pathways. This process contributes to the formation of AS plaques in ApoE−/− mice11. Further studies have shown that the expression of multiple olfactory receptors in macrophages is upregulated in mouse AS plaques, with Olfr2 being highly expressed in vascular macrophages17. Olfr2 shares homology with OR6A2 in human macrophages, and its expression level is significantly correlated with the progression of atherosclerotic plaques. The Olfr2-responsive ligand, octanal, promotes the activation of the nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, which induces the release of interleukin-1β (IL-1β). This exacerbates AS, elevates octanal levels, and further increases Olfr2 expression in atheromatous plaques17. While previous studies have underscored the critical role of Olfr2 and its ligand octanal in promoting AS, further exploration of the underlying mechanisms driving octanal/Olfr2-induced AS remains essential. Sodium-hydrogen exchanger 1 (NHE1), the first cloned member of the NHE gene family, is widely expressed in the cell membranes of various cell types20,21. Structurally, NHE1 consists of two main regions: an initial transmembrane region and an intracellular regulatory region at the carboxy terminus. The transmembrane region includes an ion channel domain responsible for the exchange of extracellular Na+ and intracellular H+ in a 1:1 ratio, primarily regulating intracellular pH and cell volume22. In recent years, the role of NHE1 in AS has attracted considerable attention. The acidification of plaque lesions is a critical pathological feature of AS, and NHE1 is highly expressed in atheromatous plaques, playing a key role in plaque acidification and the progression of AS23,24. Notably, knockout or inhibition of the NHE1 gene has been shown to significantly slow the progression of AS25,26. These findings highlight the substantial role of NHE1 in facilitating both the onset and progression of AS. NHE1 contributes to the pathogenesis of AS through several potential mechanisms. In atherosclerotic plaques, NHE1 activity may regulate the survival and function of macrophages and endothelial cells. Intracellular acidification activates NHE1, which counteracts acidification in macrophages or foam cells within plaques, thereby enhancing their survival and reducing apoptosis. Simultaneously, a reduction in extracellular pH within plaques may destabilize the plaques. Additionally, NHE1 activation is closely associated with the Ca2+ signaling pathway. Disruptions in the intracellular and extracellular Ca2+ balance lead to the upregulation of NHE1-regulated inflammatory cytokines, with the Ca2+ pathway being critical for NHE1 activation27. Ca2+-dependent signaling orchestrates key processes, such as inflammation, cell death, proliferation, and migration, during AS progression28,29. Elevated Ca2+ ion concentrations promote the binding of Ca2+/CAM to a specific region of the NHE1 protein, comprising amino acids 636 to 656. This interaction activates NHE130, resulting in increased ROS production. Given that both octanal/Olfr2 and NHE1 are implicated in driving AS, and both can elevate Ca2+ levels and ROS generation17,27, a feedback loop may be hypothesized, whereby NHE1 amplifies AS progression by further increasing Ca2+ and ROS production. Specifically, octanal binding to Olfr2 is expected to induce a substantial rise in free Ca2+ in cells. This increase in Ca2+ could facilitate the binding of Ca2+/CAM to NHE1, thereby activating it and accelerating AS progression. The subsequent activation of NHE1 may cause an additional rise in Ca2+ levels, intensifying the disease process and establishing a harmful feedback cycle. Furthermore, NHE1 activation may exacerbate AS by triggering oxidative stress via elevated ROS levels. To test this hypothesis, the expression and activity of NHE1 were assessed following octanal intervention. The impact of NHE1 inhibition on Ca2+ release, ROS production, inflammatory mediator release, and foam cell formation induced by octanal was also evaluated. Mechanistic insights were further obtained through Olfr2 knockdown and calcium ion chelation. Finally, an NHE1+/−ApoE−/− mouse model was developed to confirm the role of NHE1 in octanal-induced AS. This investigation aims to elucidate the role and mechanisms of NHE1 in the onset and progression of AS driven by NHE1 and octanal/Olfr2, enhance the theoretical understanding of “olfactory dysfunction” in AS, and provide experimental support for the development of novel anti-AS strategies targeting NHE1 and octanal/Olfr2. Results Octanal promoted atherosclerosis and upregulated NHE1 expression in plaques Octanal exacerbates AS by activating olfactory receptors16. Additionally, the activation of NHE1 has been implicated in promoting the development of AS 23. To assess the impact of octanal on AS in mice, histological staining was performed (Fig. 1A-D). Mice fed a high-fat diet (HFD) displayed increased atherosclerotic plaques, with associated intimal thickening, lipid accumulation, inflammatory responses, and collagen deposition (P < 0.01). Treatment with octanal (HFD + octanal) further aggravated these lesions (HFD + octanal vs. HFD; P < 0.001), corroborating previous findings. Additionally, the expression of NHE1 in plaques was evaluated through immunohistochemistry (Fig. 1E, F) and Full-field original micrographs are provided as Supplementary (Fig S3), revealing that octanal not only promoted plaque formation but also induced high expression of NHE1 (HFD + octanal vs. HFD; P < 0.0001). These results suggest that NHE1 is involved in the process of octanal-induced atherosclerotic plaque formation. Octanal causes a high level of NHE1 expression in plaques Effect of NHE1 on octanal-induced atherosclerosis was assessed using aortic sinus sections from ApoE−/− mice on Normal diet group, high-fat diet group, high-fat diet + octanal group. These sections underwent hematoxylin and eosin (H&E) staining, oil red O staining and Masson’s trichrome staining (A) (scale bar = 150 μm). Subsequent statistical analyses were conducted on the results of H&E staining (B), oil red O staining (C), Masson’s trichrome staining (D). NHE1 immunohistochemistry (scale bar = 1000 μm) (E), NHE1 statistical analysis (F).CON: normal diet group; HFD: high-fat diet; Oct: octanal; One-way ANOVA results are presented as mean ± SD (n = 6). Statistical significance is indicated as follows: * P < 0.05, ** P < 0.01, *** P < 0.001. The expression and activity of NHE1 protein were significantly increased in RAW264.7 macrophages in response to Octanal stimulation To investigate the effect of octanal on NHE1 protein expression and activity in RAW264.7 macrophages, a series of experiments were conducted. In vitro studies demonstrated that octanal increased NHE1 protein expression in a time- and concentration-dependent manner (Time 12 h vs. 24 h P < 0.01;Octanal 10 µM vs.20 µM P < 0.05) (Fig. 2 A, B). The intracellular pH was assessed using BCECF-AM fluorescent probes, and the findings showed that intracellular fluorescence intensity increased with higher octanal concentrations (Octanal 20 µM vs. 40 µM P < 0.05) (Fig. 2 C, D), further supporting the regulatory influence of octanal on intracellular pH. NHE1 activity was evaluated by measuring the pH recovery rate after NH4Cl-induced acidification. The octanal treatment group exhibited a significantly enhanced pH recovery rate compared to the control group, suggesting that octanal promotes NHE1 activity (Fig. 2E). In contrast, administration of the NHE1-specific inhibitor Cariporide resulted in a marked decrease in both NHE1 activity and intracellular pH (Oct vs. Ctrl P < 0.01; Oct vs. Oct + Car P < 0.05) (Fig. 2 F, G), confirming the stimulatory effect of octanal on NHE1 activity. In summary, these experimental findings demonstrate that octanal significantly enhances NHE1 protein expression and activity in RAW264.7 macrophages, establishing a critical foundation for understanding the role of octanal in cellular physiological processes. NHE1 expression and activity enhanced by Octanal (A) and (B) In vitro experiments demonstrate the expression levels and statistical analysis of NHE1 protein in RAW264.7 cells subjected to octanal treatment for varying durations or at different concentrations. (C) Fluorescence images depicting pH alterations in RAW264.7 cells exposed to different concentrations of octanal, visualized using a BCECF-AM probe (scale bar = 50 μm). (D) Statistical comparison of each experimental group against the 0 µM octanal control group. (E) Analysis of the intracellular pH change curve following acid load induced by NH4Cl, (F) assessment of the resting intracellular pH value, and (G) evaluation of NHE1 activity during the resting state. experiment results n = 3 are presented as mean ± SD (standard deviation). Car: cariporide.* P < 0.05; ** P < 0.01; **** P < 0.0001. Inhibition of NHE1 activity alleviated the formation of RAW264.7 foam cells and inflammation caused by Octanal CCK-8 identified 20 µM octanal as the lowest concentration that significantly reduced RAW264.7 viability (Fig. S1), and Western blot confirmed that this dose markedly up-regulated NHE1 (Fig. 2B); it was therefore adopted as the minimal effective in vitro dose for all subsequent experiments. Macrophage phagocytosis of LDL-C and ox-LDL, which leads to foam cell formation in early atherosclerotic plaques, is essential for AS progression32. To explore the role of NHE1 in octanal-induced AS, a foam cell model was established using ox-LDL with or without octanal and treated with an NHE1 inhibitor. The results showed that ox-LDL increased intracellular lipid content compared to controls. Octanal further enhanced lipid accumulation, indicating exacerbated foam cell formation. However, co-treatment with the NHE1 inhibitor cariporide significantly reduced lipid accumulation (oxLDL vs. oxLDL + Oct P < 0.001; oxLDL + Oct vs. oxLDL + Oct + Car P < 0.001) (Fig. 3A, B). Additionally, cells were treated with LPS ± octanal or NHE1 inhibitors, followed by western blot and qPCR analyses. Exposure to LPS and octanal significantly increased NLRP3, IL-6, and IL-1β levels (Lps + Oct vs. Lps P < 0.01; Lps + Oct vs. Lps + Oct + Car P < 0.001) (Fig. 3C-I). These increases were attenuated by NHE1 inhibition, suggesting that inhibiting NHE1 mitigates foam cell formation and inflammation in RAW264.7 cells induced by octanal. Olfr2 knockdown reduced NHE1 activity and decreased the inflammatory response To investigate whether NHE1’s involvement in AS is linked to olfactory receptors, RNA interference was used to knock down Olfr2 in RAW264.7 cells(Fig. 4A), and its effects on NHE1 activity and inflammation were examined. Olfr2 knockdown significantly reduced both NHE1 protein and mRNA levels (siNC + Oct vs. siOlfr2 + Oct P < 0.01) (Fig. 4B, C). BCECF-AM and NH4Cl loading assays confirmed that Olfr2 knockdown diminished NHE1 activity (siNC + Oct vs. siOlfr2 + Oct P < 0.01), as indicated by a lower intracellular pH (siNC + Oct vs. siOlfr2 + Oct P < 0.001) (Fig. 4D, E). Western blot and qPCR analyses further revealed that Olfr2 knockdown markedly reduced the expression of inflammatory cytokines NLRP3, IL-6, and IL-1β at both protein (siNC + Oct vs. siOlfr2 + Oct P < 0.0001) and mRNA levels (siNC + Oct vs. siOlfr2 + Oct P < 0.01) compared to controls (Fig. 4F-H). Additionally, the NHE1 inhibitor cariporide further reduced the octanal-induced inflammatory response in Olfr2-knockdown cells, though this effect was not statistically significant when compared to octanal treatment alone. These results suggest that Olfr2 knockdown reduces NHE1 activity and significantly inhibits octanal-induced inflammation in RAW264.7 cells. Octanal-induced foam cell formation and inflammatory responses damped by specific NHE1 inhibitor cariporide. (A) Oil Red O staining (scale bar = 20 μm).(B) Intracellular lipid deposition.(C) Western blot analysis of NLRP3, IL-6 and IL-1β protein expression.(D) NLRP3 protein levels.(E) IL-1β protein levels.(F) IL-6 protein levels.(G) qPCR analysis of NLRP3 mRNA expression.(H) qPCR analysis of IL-1β mRNA expression.(I) qPCR analysis of IL-6 mRNA expression. n = 3; **P < 0.01; *** P < 0.001; **** P < 0.0001. Calcium elevation and ROS-dependent NLRP3 inflammasome activation drove octanal-induced macrophage inflammation via NHE1 signaling This study further elucidated the mechanistic role of NHE1 in the inflammatory response triggered by octanal in RAW264.7 macrophages. RAW264.7 cells were treated with lipopolysaccharide (LPS) and octanal, with an intervention group treated with an NHE1 inhibitor and BAPTA-AM, a calcium ion chelator. The results showed that LPS and octanal treatment significantly increased intracellular calcium fluorescence intensity, an effect that was notably attenuated by the NHE1 inhibitor and BAPTA-AM (Lps + Oct vs. Lps + Oct + Car P < 0.01; (Lps + Oct vs. Lps + Oct + BAPTA-AM P < 0.001) (Fig. 5A, B). Concurrently, ROS levels were markedly elevated following LPS and octanal treatments, but this increase was mitigated by NHE1 inhibition (LPS + Oct + Car vs. LPS + Oct; P < 0.0001) (Fig. 5C). Western blot and qPCR analyses showed that LPS and octanal treatments upregulated NHE1 expression (LPS + Oct vs. LPS; P < 0.001), while BAPTA-AM reduced NHE1 expression (Lps + Oct vs. Lps + Oct + BAPTA-AM P < 0.01) (Fig. 5D, E). Furthermore, the activation of NHE1 led to an upregulation of inflammatory cytokines NLRP3, IL-1β, and IL-6, all of which were significantly reduced by NHE1 inhibition and BAPTA-AM treatment (Lps + Oct vs. Lps + Oct + BAPTA-AM P < 0.01) (Fig. 5F-H). Together, these results suggest that NHE1 activation enhances octanal-induced ROS production and calcium influx, promoting inflammatory responses through oxidative stress and calcium signaling pathways. Effect of Olfr2 knockdown on NHE1 activity and inflammatory factors.(A)Knockdown protein expression level of Olfr2 (B) NHE1 protein expression in Raw264.7 cells after Olfr2 knockdown and octanal treatment. (C) NHE1 mRNA expression levels. (D) Intracellular pH measured with BCECF-AM probe. (E) NHE1 activity assessed by NH4Cl loading experiments.(F) Protein levels of inflammatory markers after Olfr2 knockdown.(G) Statistical analysis of inflammatory markers.(H) mRNA expression of IL-6, NLRP3, and IL-1β. n = 3, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Genetic inhibition of NHE1 alleviated atherosclerosis and inflammation caused by Octanal To investigate NHE1’s role in octanal-induced AS, NHE+/+ ApoE−/− and NHE+/−ApoE−/− mice were fed an HFD with or without octanal (i.p.) for 12 weeks. It can be observed that in the HFD + Oct group group, the plaque area at the aortic arch and aortic root was significantly increased (Fig. 6A). Histological analysis revealed that HFD + Oct-treated NHE+/+ ApoE−/− mice exhibited more severe atherosclerotic lesions in the aortic roots, characterized by increased intimal thickening, lipid deposition, and inflammatory cell infiltration compared to the HFD-only group (P < 0.01). In contrast, NHE1 heterozygous mice (NHE+/−ApoE−/−) in the HFD + Oct group exhibited reduced lesion severity, marked by decreased intimal thickening, lipid deposition, and inflammation (P < 0.05) (Fig. 6B, C). qPCR analysis showed significant upregulation of inflammatory cytokines (NLRP3, IL-1β, IL-6) in wild-type mice treated with HFD + Oct (P < 0.0001), which was significantly attenuated in NHE1 heterozygous mice (P < 0.001) (Fig. 6D). Immunohistochemical analysis demonstrated a marked reduction in intraplaque macrophage infiltration in NHE1 heterozygous mice compared with wild-type mice fed an HFD + Oct(Fig. 6E, F).These results suggest that genetic inhibition of NHE1 alleviates octanal-induced AS and inflammation. Macrophage inflammation induced by octanal was driven by NHE1 signaling, involving calcium elevation and ROS-dependent activation of the NLRP3 inflammasome (A) Images and (B)Statistical analysis for calcium fluorescence intensity in different treatment groups (scale bar = 50 μm). (C) ROS levels (DCF fluorescence intensity) in different treatment groups.(D) Protein expression levels of NHE1.(E) mRNA levels of NHE1(F)the protein levels and (G) corresponding statistical analysis for inflammatory factors induced by octanal after treatment with BAPTA-AM or NHE1 inhibitors; (H) Statistical analysis for mRNA levels of inflammatory factors.* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Octanal-Induced Atherosclerosis and Inflammation in ApoE−/−NHE+/− Mice. (A) images of atherosclerotic plaque in the aortic arch of NHE+/+ ApoE−/− and NHE+/−ApoE−/− mice with or without high-fat diet (HFD) or plus octanal(OCT) (B-C) histological characteristics and quantitative analysis for the aortic sinus from NHE+/+ ApoE−/− and NHE+/−ApoE−/− mice under high-fat diet (HFD) or plus octanal(OCT) (scale bar = 150 μm). (D) qPCR analysis for inflammatory cytokine expression in mouse aortic tissue. (E-F) CD68 immuno-histochemical staining measurement of macrophage content; Data from Animal experiments (n = 6) and Cell experiment (n = 3) are presented as mean ± SD (standard deviation). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Discussion Macrophage inflammation and foam cell formation are key contributors to the initiation and progression of AS31. Octanal, a product of lipid peroxidation, binds to Olfr2 on macrophages, thereby promoting the advancement of AS. Moreover, NHE1 plays a critical role in the acidification and progression of atherosclerotic plaques25. However, the interaction between octanal, Olfr2, and NHE1, along with their specific mechanisms in AS progression, remains insufficiently understood. This study presents several key findings: firstly, both in vivo and in vitro experiments demonstrated that octanal upregulates NHE1 expression and activity. Secondly, inhibition of NHE1 was shown to mitigate octanal-induced Ca2+ influx, ROS production, inflammatory cytokine release, and foam cell formation. Mechanistically, Olfr2 knockdown and the application of BAPTA-AM were found to decrease NHE1 expression and its associated inflammatory response. Finally, NHE1 knockdown was experimentally shown to reduce octanal-induced AS through genetic inhibition of NHE1. These findings, for the first time, establish that NHE1 functions as a downstream effector in the octanal/Olfr2 signaling axis involved in atherosclerotic plaque formation. This provides a theoretical basis for the development of novel therapeutic strategies targeting NHE1 and the octanal/Olfr2 pathway in AS. As a chronic inflammatory disease, AS is closely associated with macrophage dysfunction. Plasma concentrations of octanal in both humans and mice are sufficient to activate Olfr2 and human olfactory receptor 6A2 (OR6A2) on macrophages17. Recent studies have linked elevated octanal levels to the exacerbation of AS, particularly through the involvement of Olfr2 in AS pathogenesis35 In AS lesions, Olfr2-positive macrophages exhibit a pro-inflammatory, foam cell phenotype. These macrophages accumulate extensively in atherosclerotic plaques, demonstrating both proliferative and pro-inflammatory characteristics33,34. In vivo and in vitro experiments revealed that octanal treatment significantly increased atherosclerotic plaque area, lipid deposition, and intimal thickening compared to HFD alone. Additionally, RAW264.7 cells showed a marked inflammatory response to octanal, consistent with previous studies17. Notably, this study identified that octanal promotes high expression of NHE1. In recent years, extensive research has effectively reduced the formation of AS plaques by targeting the inhibition of Olfr2 activity or blocking its signaling pathway. For example, corilagin has been shown to alleviate the inflammatory response in AS by inhibiting NLRP3 inflammasome activation within the Olfr2 signaling pathway35. Furthermore, a small interfering RNA (siRNA) nanoparticle delivery system targeting Olfr2 has been demonstrated to downregulate Olfr2 expression in macrophages, reduce inflammasome activation, and decrease IL-1β secretion, thereby inhibiting plaque formation36. Furthermore, Olfr2 was knocked down via RNA interference, and the results revealed that Olfr2 knockdown mitigated the octanal-induced inflammatory response. The activation mechanisms of the NLRP3 inflammasome encompass K + efflux, Ca2 + influx, cathepsin release from lysosomes, and increased production of reactive oxygen species (ROS)37,38. Inhibition of NHE1 can reduce ROS production and reduce inflammatory response39. Notably, this study is the first to report a significant increase in NHE1 expression following octanal treatment in both in vivo and in vitro models, with a subsequent decrease in NHE1 expression following Olfr2 knockdown. These results suggest that octanal plays a pivotal role in AS pathogenesis by activating Olfr2 to enhance NHE1 expression. NHE1 plays a pivotal role in regulating intracellular pH and cell volume, which are essential for various physiological processes, including cell growth, proliferation, migration, and apoptosis40. Dysregulation of NHE1 activity has been linked to a range of human pathologies, including cardiovascular and cerebral injuries related to ischemia and reperfusion, cardiac hypertrophy, tumor cell proliferation, and neurological disorders41–44. NHE1 overexpression has been shown to promote M1 macrophage polarization and accelerate AS progression, while its inhibition delays the onset of the disease45,46. However, the involvement of NHE1 in octanal-induced AS remains unexplored. Our findings confirm that aortic plaque lesions in octanal-treated mice were exacerbated compared to those in the HFD group, with a significant increase in NHE1 expression within the plaques. In vitro experiments further corroborated these results, showing that NHE1 expression increased with rising octanal concentrations. Moreover, inhibiting NHE1 activity was found to mitigate the inflammatory response induced by octanal. Subsequent experiments involved administering octanal to NHE1+/+ApoE−/− and NHE1+/−ApoE−/− mice. Compared to the NHE1+/+ApoE−/− group, the NHE1+/−ApoE−/− group exhibited a significant reduction in plaque area, lipid deposition, and inflammatory cell infiltration, with statistically significant differences observed. These findings suggest that NHE1 plays a critical role in the promotion of octanal-induced AS, consistent with previous studies indicating that NHE1 inhibition can alleviate AS progression47. The precise role of NHE1 in octanal-induced AS remains unclear. NHE1 is the sole NHE subtype in the myocardium and functions primarily as a membrane protein that regulates ion balance across the cell membrane48. Under conditions such as ischemia and hypoxia, NHE1 activity increases, leading to elevated production of ROS and higher intracellular Ca2+ ion concentrations, which facilitate the progression of AS49. Further investigation is needed to determine whether NHE1’s involvement in octanal-induced AS is linked to ROS production and increased Ca2+ ion concentration. AS is a multifaceted chronic inflammatory disease, and its pathogenesis remains incompletely understood. It is hypothesized that AS develops as a chronic inflammatory response to damage inflicted on arterial endothelial cells. Within this context, a complex interplay between elevated Ca2+ levels, ROS, and the expression of inflammatory mediators creates a sophisticated pathological network. For instance, oxidative stress and inflammation mutually reinforce each other, driving the progression of AS. Furthermore, the calcium signaling pathway is intricately linked to NHE1 activity, with prior research identifying heightened NHE1 activity as a critical mediator connecting increased ROS levels to Ca2+ overload50. Octanal induces an increase in Ca2+ influx in wild-type mice. However, no significant increase in Ca2+ influx was observed in Olfr2−/− bone marrow-derived macrophages, suggesting that the elevation in Ca2+ concentration induced by octanal is closely tied to the presence of Olfr2 17. Our study demonstrates that octanal significantly enhances both Ca2+ influx and ROS production. The application of NHE1 inhibitors or calcium chelators markedly mitigates these effects, reduces NHE1 expression, and alleviates inflammation. Furthermore, octanal, by activating Olfr2, initiates a positive feedback loop mediated by the interplay between Ca2+ influx and NHE1. Specifically, binding of octanal to Olfr2 triggers an increase in intracellular Ca2+ and ROS levels, which subsequently activates NHE1. This activation of NHE1 further intensifies the elevation of intracellular Ca2+ and ROS levels, significantly amplifying the activation of the NLRP3 inflammasome. The activation of the NLRP3 inflammasome leads to the release of inflammatory factors such as IL-1β and IL-6, which are pivotal in AS progression51. Octanal enhances the expression of these inflammatory factors by binding to Olfr2, activating NHE1, and inducing Ca2+ influx and ROS production, thereby advancing AS. This finding uncovers a novel inflammatory mechanism in AS, suggesting a potential therapeutic target and emphasizing the critical role of NHE1 in the disease. Recent research has highlighted the significant role of macropinocytosis in AS. Activation of macropinocytosis promotes foam cell formation in AS mice by enhancing the excessive uptake of low-density lipoprotein (LDL) by macrophages in arterial walls. This process contributes to the formation of foam cells and accelerates the development of AS. NHE1 inhibitors have been shown to effectively reverse macropinocytosis and alleviate AS progression52,53. Macropinocytosis is an endocytic process that relies on dynamic cytoskeletal reorganization, particularly the remodeling of the microfilament network and the formation of reticular actin structures. In response to various internal and external stressors, NHE1 is activated, facilitating the exchange of extracellular Na+ for intracellular H+. This exchange triggers calcium ion influx, changes in intracellular pH and ion concentration, and further remodeling of the actin cytoskeleton, which regulates cell volume and cytoskeletal rearrangement. Inhibition of NHE1 reduces the subcortical pH of the cell, significantly inhibiting macropinocytosis and delaying the onset and progression of AS. Studies have shown that factors such as increased extracellular fluid viscosity and drug stimulation can enhance Ca2+ influx, remodel actin, and boost NHE1 activity54. Therefore, investigating whether octanal induces actin remodeling by increasing Ca2+ influx, which may promote macropinocytosis and exacerbate AS, presents a promising direction for future research. This could provide new insights into potential treatments for AS. NHE1 inhibitors have demonstrated therapeutic efficacy in various disease models by inhibiting Olfr2, regulating intracellular Ca2+ and ROS levels, and reducing macrophage uptake of LDL through the inhibition of macropinocytosis48,55. Given the potential mechanistic role of NHE1 in AS, NHE1 inhibitors may offer substantial therapeutic promise. Additionally, sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as dapagliflozin, have been shown to alleviate cellular stress and inflammation, protect aortic endothelial cells, and delay the progression of AS and aging by inhibiting NHE1 activity47,56. Moreover, the role of NHE1-mediated macropinocytosis has gained increasing attention. This endocytic process is linked not only to AS but also to the progression of other diseases, including tumor metastasis and the entry of infectious pancreatic necrosis virus into CHSE-214 cells via macropinocytosis57–59. These findings underscore the clinical relevance of NHE1 across a wide range of diseases. However, the application of NHE1 inhibitors in AS treatment remains underexplored. Further clinical investigations are needed to thoroughly assess the safety and efficacy of these inhibitors in humans, establishing a theoretical basis for their use in managing AS. Additionally, exploring the potential for enhanced therapeutic outcomes through combined administration of NHE1 inhibitors and other pharmacological agents, such as statins, may offer synergistic effects. For example, the concurrent use of NHE1 inhibitors and statins could potentially enhance the inhibition of atherosclerotic plaque formation and progression through multiple mechanisms. This study provides critical insights into the mechanism by which octanal exacerbates AS via the Olfr2-NHE1 axis, emphasizing the pivotal role of NHE1 in inflammation, oxidative stress, and Ca2+ signaling. Specifically, the enhancement of Ca2+ signaling and the activation of NHE1 are implicated in macrophage function, facilitating LDL uptake. Octanal, present in fragrances and oxLDL, plays a pivotal role in the pathogenesis of AS. Future research should explore whether the interaction between Olfr2 and its ligand octanal contributes to AS progression through macrophage-mediated mechanisms. Such investigations could offer novel strategies for combating AS by targeting octanal, Olfr2, NHE1, and macrophage activity. Although this study provides novel insights into the role of NHE1 in AS, it has several limitations. The use of NHE1 total knockout (NHE1−/−ApoE−/−) mice is limited by the onset of neurodegenerative changes in the cerebellum and brainstem, which cause ataxia and epileptic-like seizures, leading to a survival period of less than one month60. Consequently, an NHE1+/−ApoE−/− heterozygous knockout mouse model was used. Future studies should consider employing a conditional knockout (cKO) mouse model of NHE1 to more accurately evaluate its role in AS. Additionally, as this study primarily utilized cellular and murine models, further research is required to validate these findings in human samples, and subsequent experiments will be verified with bone marrow-derived macrophages and other cells; In this experiment, transient siRNA knockdown was employed. Subsequently, CRISPR-Cas9 knockout and Tet-On overexpression of RAW264.7 cells were utilized to validate the Olfr2–NHE1 axis. which would better determine the potential of NHE1 as a viable clinical therapeutic target. In summary, this study is the first to demonstrate that octanal exacerbates the progression of AS by activating NHE1 through its binding to Olfr2. These findings provide an experimental foundation for reconsidering the safety of octanal as a food additive and lay a theoretical foundation for the development of NHE1-targeted therapeutic strategies. Future research will delve deeper into the mechanistic role of the Olfr2-NHE1 axis in AS, evaluate its clinical utility as a therapeutic target, and contribute to a more comprehensive framework for the treatment of AS. Conclusion This study explores the mechanism by which octanal exacerbates AS through animal models and cellular experiments, focusing on the critical role of NHE1. The results demonstrate that octanal significantly upregulates both the expression and activity of NHE1 by activating the olfactory receptor Olfr2 in macrophages. This activation triggers an increase in intracellular calcium ion (Ca2+) levels and the production of ROS. These processes not only facilitate foam cell formation but also amplify the inflammatory response, contributing to the progression of atherosclerotic plaques. Further investigation revealed that octanal-induced activation of Olfr2 establishes a positive feedback loop, where the interaction between Ca2+ and NHE1 exacerbates the elevation of intracellular Ca2+ and ROS levels. This feedback mechanism significantly enhances the expression of inflammatory cytokines, such as NLRP3, IL-1β, and IL-6, thereby accelerating the pathological progression of AS. Inhibition of NHE1 activity, either through pharmacological inhibitors (e.g., cariporide) or genetic knockdown, markedly reduces octanal-induced atherosclerotic lesions, underscoring the pivotal role of NHE1 in this process. These findings clarify the primary mechanism through which octanal contributes to AS via the Olfr2-NHE1 axis and provide novel insights for developing therapeutic strategies targeting NHE1. Materials and methods Antibodies and reagents Antibodies used in this study were as follows: Rabbit anti-mouse NHE1 antibody (Abcam, ab64314); Rabbit anti-mouse IL-6 antibody (Wuhan Mitaka Biotech Co., Ltd., 66146−1-Ig); β-actin antibody (Wuhan Mitaka Biologics Co., Ltd., 66009−1-Ig); Rabbit anti-mouse IL-1β antibody (WL02257, 10,000 organisms); Rabbit anti-mouse NLRP3 antibody (WL02635, 10,000 organisms); HRP-conjugated goat anti-rabbit secondary antibody (APExBIO, K4115). Reagents used were as follows: Octanal (MCE, HY-N8015); LPS (MCE, HY-D1056); CCK-8 Plus Assay Kit (APExBIO, K1018); Special fetal bovine serum (Shanghai Xiaopeng Biological Co., Ltd., C04001-050 × 10); HE staining kit (Solarbio, G1121); Masson’s trichrome staining kit (Solarbio, G1340); Oil red O staining solution (Solarbio, G1260); Bouin’s Fixative Solution (Feijing Biotech, PH0976); BCECF-AM (Solarbio, IB1750); Fluo-4AM (Biyuntian, S1060); Olfr2 antibody(ELK Biotech, ES4852);BAPTA-AM (Maucel Biotech, MX4524); High-fat feed (Beijing Boaigang Company, 1145NA). Animal experiments C57/BL6 and NHE+/− mice were generously donated by Professor Zhanhui Feng of Guizhou Medical University, whereas ApoE−/− mice were provided by Professor Hailong Ou from the same institution. The NHE1+/−ApoE−/− mice were generated through the crossbreeding of NHE+/+ApoE−/− mice with NHE+/−ApoE+/+ mice. Detailed methodologies and results pertaining to the genetic identification of these mice are presented in Supplementary Material 1 (Fig. S2).Eight-week-old male genetically modified mice with genotypes NHE1+/+ApoE−/− (n = 30) and NHE1+/−ApoE−/− (n = 6), all of C57BL/6 genetic background, were maintained under controlled environmental conditions, including a temperature of 24 ± 2 °C, relative humidity of 50 ± 10%, a 12-hour light/dark cycle, adequate ventilation, and unrestricted access to drinking water. After one week of adaptation to regular feed, NHE1+/+ApoE−/− mice were randomly divided into three groups: normal diet group, HFD group, and HFD + octanal group, with 6 mice per group. The other group consisted of NHE1+/+ApoE−/− mice randomly assigned to: HFD group, HFD + octanal group, and NHE1+/−ApoE−/− mice receiving HFD + octanal. The high-fat feed, purchased from Beijing Bogang Biotechnology Co., Ltd., contained 40% fat and 1.25% cholesterol. The HFD group received 100 µL of PBS intraperitoneally three times a week for 4 weeks. The octanal group received octanal dissolved in PBS at a concentration of 10 µg per gram of body weight, administered intraperitoneally (i.p.) as 100 µL every 3 days for 4 weeks (total of 12 injections) while maintaining an HFD. High-fat feed was stored at −20 °C, providing 5 g per animal per day and free access to drinking water. Following the dietary and treatment protocols, all mice were euthanized by carbon dioxide anesthesia, and tissues were collected for further analysis. The animal experiment was approved by the Animal Welfare Ethics Committee of Guizhou Medical University (approval number 2101044). Furthermore, all techniques were executed in compliance with the pertinent guidelines and regulations, and this study was reported following the ARRIVE guidelines. Throughout the experimental process, the 3R principles of replacement, reduction, and refinement were adhered to. Cells and cultures RAW264.7 cells(Zishan Biological Co., Ltd.; No. SSTCC20020G) were cultured in high-glucose DMEM medium supplemented with 10% premium bovine serum. Upon reaching 80% confluence, the cells were washed three times with PBS, gently pipetted using a 1 ml tip, and resuspended to a concentration of 1.5 × 105 cells/ml. A 2 ml aliquot of the cell suspension was then added to each well of a 6-well plate. Once the cells adhered, further experiments were conducted according to the experimental design. The concentration and duration of octanal intervention were ascertained using cell viability assays. Detailed methodologies and results are provided in Supplementary Material 1 (Fig. S1). Octanal (20 µmol/ml), Cariporide (5 µmol/ml), and LPS (100 ng/ml) were administered for 24 h, either individually or in combination, resulting in five experimental groups: Control, LPS, LPS + Octanal, LPS + Cariporide, and LPS + Octanal + Cariporide. Staining of cells with ORO Cells were cultured in 12-well plates, and drug intervention was administered for 24 h according to the experimental groups. After treatment, the cells were removed, and the culture medium was discarded. The cells were then washed with phosphate-buffered saline (PBS) and fixed using an Oil Red O fixative solution for 30 min. After discarding the fixative, the cells were washed three times with double-distilled water (ddH2O) and treated with 500 µL of 60% isopropanol for 6–8 s to permeabilize the cells. The isopropanol was then aspirated, and 500 µL of Oil Red O staining solution was added dropwise to each well. The cells were stained at room temperature, protected from light, for 30 min. Afterward, the Oil Red O staining solution was discarded, and the cells were washed with 60% isopropanol to remove excess stain, followed by five gentle washes with ddH2O until no residual staining solution remained. Hematoxylin staining solution was then applied to counterstain the nuclei for 1 min. After discarding the staining solution, the cells were washed three times with ddH2O to eliminate excess stain. An Oil Red O buffer was then added for 1 min, after which the buffer was discarded, and 200 µL of ddH2O was added to each well to cover the cells. The stained cells were examined using a light microscope, and images were captured for analysis. Mouse aortic sections stained with ORO The hearts were embedded in optimal cutting temperature (O.C.T.) compound and subsequently frozen at − 80℃.The frozen tissues were sectioned in a layer-by-layer manner, with each section having a thickness of 8 μm, starting from the aortic sinus, utilizing a cryo-cut microtome. The aortic sinus sections were fixed, a For frozen sections, samples were restored to room temperature and soaked in PBS for 3 min. They were fixed with 4% paraformaldehyde for 10 min and then soaked in distilled water for 3 min. The sections were immersed in 60% isopropanol for 6–10 s. Excess water was removed, and the Oil Red O working solution was applied for 20 min. The sections were differentiated with 60% isopropanol for 5–10 s until the interstitium was clear, after which differentiation was terminated by immersion in distilled water. The sections were stained with hematoxylin, washed, reversed blue, and sealed with glycerol gelatin. The areas of lesions were measured by morphometric analysis of the acquired images using ImageJ software. Correlation analyses were conducted using GraphPad Prism. HE staining of mouse aorta Frozen sections were allowed to thaw at room temperature, fixed with 4% paraformaldehyde for 10 min, and then rinsed with distilled water three times, with each rinse lasting 5 min. The sections were stained with hematoxylin for 5 min, followed by three 3-minute rinses. Excess hematoxylin was removed by dipping the sections in a 1% hydrochloric acid differentiation solution for 1–2 s, then rinsed with slow-flowing tap water for 10 min to restore the blue color. Eosin staining was then applied for 30 s. The sections were dehydrated, cleared, and mounted with neutral resin dropwise. Images were captured using an optical microscope. Masson staining of mouse aorta Frozen sections were rinsed, fixed overnight with Bouin’s fixative solution, and washed with distilled water. A1 and A2 components of the Masson trichrome kit were prepared into a Weigert iron hematoxylin staining solution, which was applied to the sections for 10 min, followed by washing away excess stain with distilled water. An acidic differentiation solution was applied for 5–15 s, followed by rinsing with distilled water for 30 s. Masson bluing solution was added dropwise for 5 min, and the sections were rinsed with distilled water for 30 s. Ponceau red staining solution was added dropwise for 3 min, followed by application of weak acid working solution for 30 s, and excess liquid was poured off. Aniline blue staining was applied dropwise for 1–2 min, followed by washing with a weak acid working solution for 30 s. The sections were dehydrated in ethanol, cleared in xylene, and sealed with neutral resin. Immunohistochemistry for detection of NHE1 expression For immunohistochemistry, frozen sections were brought to room temperature, fixed with cold acetone for 10 min at 4 °C, and rinsed three times with PBS for 5 min each. The sections were treated with 3% hydrogen peroxide for 30 min, followed by three PBS washes. Primary antibodies for NHE1 (1:100 dilution) were incubated overnight at 4 °C. After three PBS washes, a secondary antibody was added and incubated at room temperature for 60 min. Color development was achieved using DAB, followed by counterstaining with hematoxylin, dehydration, and mounting. Photographs were taken. Paraffin sections were deparaffinized to water, subjected to antigen retrieval, and then analyzed using ImageJ Pro Plus 6.0 software. Western blot analysis Following experimental interventions, the cells were lysed using ice-cold RIPA buffer containing protease and phosphatase inhibitors. The proteins were denatured by heating with a loading buffer at 100 °C for 10 min. SDS-PAGE electrophoresis was performed, followed by a wet transfer process. The membrane was blocked with 5% skim milk for 1 h at room temperature, the membranes were precisely trimmed according to the molecular weights of the target proteins. and incubated overnight with the primary antibody at 4 °C. The secondary antibody was applied and incubated for 1 h at room temperature. ECL was used for color development, and ImageJ software was employed for gray value analysis. Quantitative PCR detection Total RNA was extracted from cells subjected to various interventions using Trizol reagent (ThermoFisher, AM9738) and subsequently converted into cDNA following the instructions of the reverse transcription and PCR kit. Amplification was performed in a 10 µL reaction system using a real-time PCR instrument, with conditions set at 95 °C for 2 min, followed by 40 cycles of 95 °C for 10 s and 60 °C for 30 s. The primer sequences were designed as follows: Mouse NHE1 gene (forward: 5’-CCGCTCTTCGTCTTCCTC-3’, reverse: 5’-ATGGTGGTGTGGGATTTGTGT-3’), NLRP3 gene (forward: 5’-CCTTATCCACTGCCGAGAG-3’, reverse: 5’-AGCTCATCAAAGCCATCC-3’), IL-1β (forward:5’-CCCTGCAGCTGGAGAGTGGA-3’, reverse: 5’-CTGAGCGACCTGTCTTGGCCG-3’), IL-6 (forward: 5’-CACGGCCCTTCCCTACTTC-3’, reverse: 5’-TTTCCACGATTTCCCAGA-3’), and β-actin (forward: 5’-AGAGGGAAATCGTGCGTGACA-3’, reverse: 5’-CACTGTGTTGGCATAGAGGTC-3’). These primers were synthesized by Shanghai Biotechnology Co., Ltd. The Ct values of all samples were obtained using a fluorescence quantitative PCR instrument, and the relative gene expression was calculated using the 2−△△Ct method. Determination of reactive oxygen species generation RAW264.7 cells were seeded in 96-well plates at a concentration of 1 × 105 cells/mL. After incubation at 37 °C with 5% CO2, the medium was replaced, and the cells were stimulated with or without 50 ng/mL of LPS for 4 h. The LPS-pretreated cells were further incubated with octanal, cariporide, and a calcium ion chelating agent. Reactive oxygen levels at different time points were measured using a multifunctional microplate reader set to 37 °C. Data analysis was performed using GraphPad Prism software. Evaluation of the fluorescence intensity using BCECF-AM To investigate intracellular pH changes following octanal treatment, cells were seeded in 6-well plates at a density of 1.5 × 105 cells/mL. Once approximately 80% confluence was reached, cells were exposed to varying concentrations of octanal for 24 h. Afterward, the cells were washed three times with PBS and incubated with the BCECF-AM probe in HEPES buffer at a concentration of 3 µM for 30 min. Following another PBS wash, fluorescence microscopy was employed to assess fluorescence intensity. Image J software was used for quantitative analysis of fluorescence intensity. Detection of pH recovery rate (NHE1 activity) To assess NHE1 activity, at least 1000 cells per well were seeded into 96-well plates. Once the cells adhered, they were washed three times with PBS. The cells were then incubated with BCECF-AM at a final concentration of 3 µM in HEPES buffer for 30 min, followed by washing with PBS. Fluorescence intensities under dual excitation conditions (EX/EM = 490/530 nm and EX/EM = 440/530 nm) were measured using fluorescence microscopy. The fluorescence intensity ratio of the two emission wavelengths at the same excitation wavelength (490/440) was calculated. The intracellular pH recovery rate after acid loading was assessed by incubating the cells in 30 mM NH₄Cl solution for 3 min, followed by a 5-minute rinse with sodium-free solution containing either octanal or octanal plus cariporide to maintain intracellular acidosis. The cells were then rinsed with a sodium-containing solution. The intracellular pH standard curve was constructed as referenced in 59, using the ratio of pH values and corresponding fluorescence intensity to determine the regression equation and construct the curve. Transfection of SiRNA siRNA targeting the olfr2 gene was purchased from Shiga, Japan, with the sequence: 5’-CUGUUGUGAUUAUCUUCUAUG-3’. The transfection process involved culturing RAW264.7 cells in DMEM medium with 10% FBS. Twenty-four hours prior to transfection, cells were seeded into 12-well plates at a density of 5 × 104 cells per well. After incubation at 37 °C with 5% CO2 for 24 h, transfection was carried out when the cell density reached 40–50%. The GP-transfect-Mate transfection reagent was placed at room temperature and mixed gently. A total of 100 µL OPTI-MEM was added to a 1.5 mL sterile centrifuge tube, followed by the addition of 5 µL of transfection reagent, mixed gently, and incubated for 5 min at room temperature. In a separate 1.5 mL sterile centrifuge tube, 100 µL of OPTI-MEM was added along with 100 pmol of RNA oligo, mixed gently, and incubated for 5 min at room temperature. The GP-transfect-Mate reagent was then added to the RNA oligo medium mixture, mixed gently, and allowed to stand for 15–20 min at room temperature before transfection. The medium in the 12-well plates was replaced with 0.8 mL of preheated fresh medium per well. Subsequently, 200 µL of the transfection mixture was added dropwise to each well, resulting in a final volume of 1000 µL per well. The plates were gently shaken to ensure even distribution of the complex. After 6–8 h of transfection, the medium was replaced with a complete medium. protein expression was also detected at 48 h(Fig. 4A,), and mRNA expression was assessed at 24 h༈Fig. S4A༉.Subsequent experiments were performed after a minimum incubation of 24 h. Statistical methods Image analyses were performed using Fiji (ImageJ 2.14.0; https://imagej.net/software/fiji/downloads) for rquantitative evaluation of immunoblot bands and immunofluorescence signals. The experimental data were analyzed and visualized using GraphPad Prism software (version 9.5.1). Prior to analysis, all measurement data were checked for normality and homogeneity of variance. For comparisons between two groups meeting the criteria for normal distribution and homogeneity of variance, the t-test was applied. For multiple group comparisons, one-way ANOVA was used. Measurement data conforming to a normal distribution are expressed as mean ± standard deviation. When groups had unequal variance or non-normal distribution, the Kruskal-Wallis H test was applied. A p-value of less than 0.05 was considered statistically significant. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Author contributions Tianhui Wang made the most important contribution to this manuscript.The study was conceived and designed by Wang TH and Mo XG. Experiments were performed by Wang TH. Data collection by Wang TH, Wang L, Tian Q, Zhu Y, Shao LJ, Zeng J, Zhang Y. Data analysis were carried out by Wang TH,Yu YC, Su XM, Chen JH, and Li ZHL. Data interpretation and manuscript drafting were completed by Wang TH and Mo XG. All co-authors reviewed and approved the manuscript before submission. Funding The research is supported by: National Science Foundation of China, (No. 82160097, No.31660288) to Xiangang Mo; Funded by the Science and Technology Fund of Guizhou Provincial Health Commission: (No.gzwkj2024-082) to Tianhui Wang. Data availability Yes, I have research data to declareData is provided within the manuscript and its supplementary information files. Declarations Competing interests The authors declare no competing interests. Ethical approval Research Approval Statement: This research protocol received review and approval from the Laboratory Animal Welfare Ethics Committee at Guizhou Medical University. Approval number: 2101044. this study was reported following the ARRIVE guidelines. Animal rights 3R principle of replacement, reduction and refinement was followed in the process of this experimental research. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement Yes, I have research data to declareData is provided within the manuscript and its supplementary information files.